Do vonoprazan-based therapies cure Helicobacter pylori infection in 94% of Asian patients according to recent studies?
Vonoprazan is a newer acid-blocking drug that may work better than standard proton pump inhibitors (PPIs) for treating H. pylori infection. A recent large meta-analysis of Asian patients found that vonoprazan-based therapies — including dual, triple, and quadruple regimens — achieved a pooled eradication rate of 94% 6. However, other studies show that results can vary depending on the specific antibiotics used and local resistance patterns 89.
What the research says
A 2025 meta-analysis of 22 clinical studies with 7,498 participants examined vonoprazan combined with amoxicillin in various regimens for first-line H. pylori treatment in Asian populations. The overall eradication rate was 94% (95% CI: 91%–96%) 6. Dual therapy (vonoprazan + amoxicillin) achieved 92%, triple therapy (adding clarithromycin) 93%, and quadruple therapy (adding two antibiotics) 96% 6. This suggests vonoprazan-based regimens are highly effective in Asian patients.
However, a 2025 randomized trial in Egypt found lower rates: vonoprazan dual therapy eradicated 76.2% and vonoprazan triple therapy 79.2%, which were not significantly better than standard PPI triple therapy (70%) 9. This highlights that effectiveness can differ by region and antibiotic resistance patterns.
A broader meta-analysis of 57 studies (19,941 participants) across various regimens reported a pooled eradication rate of 83.0% 8, indicating that while vonoprazan shows promise, real-world success depends on multiple factors including local resistance and treatment adherence.
What to ask your doctor
- Is vonoprazan available in my country, and is it recommended for first-line H. pylori treatment?
- What eradication rate can I expect with vonoprazan-based therapy given local antibiotic resistance patterns?
- Should I have antibiotic susceptibility testing before starting treatment to improve my chances of cure?
- What are the potential side effects of vonoprazan compared to standard PPI-based therapies?
- If vonoprazan is not available, what alternative regimens have the highest success rates in my region?
This question is drawn from common patient questions about Gastroenterology and answered using cited medical research. We do not provide individualized advice.